A Phase I Study of TP-3654 in People with Myelofibrosis


Full Title

A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis


The purpose of this study is to find the highest dose of the investigational drug TP-3654 that can be given in people with myelofibrosis that persists despite treatment. Myelofibrosis happens when bone marrow cells called fibroblasts make too much fibrous (scar) tissue and the bone marrow is not able to make enough normal blood cells. TP-3654 blocks enzymes that help the abnormal cells to survive, which may cause these cells to die and slow or stop myelofibrosis. TP-3654 is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have intermediate-risk or high-risk myelofibrosis that cannot be successfully treated with other therapies.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Tamanna Haque at 646-608-4166 or email [email protected].




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID